Pacanalotamab

帕卡那妥单抗

Report date: 2026/03/23 20:03:44

Base Information

Drug NamePacanalotamab
Drug Alias NameAMG-420BI-836909
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > T cell engagers
Mechanisms of ActionAnti-BCMAT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsB-cell maturation proteinT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMicromet Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgBeOne Medicines LtdAmgen Inc
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A